Edited immune cells can be steered with existing drugs, in lab

Take a patient's immune cells out, fix them in a lab, and put them back. That is the promise of cell and gene therapy, and the trouble starts once the cells are home. In the body, clinicians have limited ways to selectively boost or suppress them, and the drugs that protect a transplanted organ or control disease can also suppress the very cells meant to treat the patient. An Australian team led by WEHI researchers now reports a way around that clash, in a study published in Blood.

The method relies on prime editing, a gene-editing technique that makes precise changes to DNA. The researchers worked with cells from people with subcutaneous panniculitis-like T-cell lymphoma with HLH, a rare and serious immune-related blood cancer that can affect children and young adults. They used prime editing to correct a disease-causing mutation, then added a second edit that made the corrected cells resistant to tacrolimus, a commonly used immunosuppressive drug, while keeping them sensitive to cyclosporin, a related alternative. The idea is a 'control dial': one drug can help the corrected cells survive while other immune cells are suppressed, and the other remains available if the edited cells behave unexpectedly and need to be scaled back. Dr. Miles Horton, a WEHI researcher and paediatrics resident at the Royal Children's Hospital, put the logic plainly: the team wanted clinicians to use drugs "already sitting in the hospital pharmacy" rather than adopting a new cell therapy and a new drug at the same time.

The platform was then tested beyond that single disease. According to the researchers, the same strategy worked in other kinds of therapeutic T cells, including virus-specific T cells that could one day help transplant recipients fight infection without stopping anti-rejection drugs, and CAR T cells, which are engineered to treat cancer. The first author, Dr. Esther Bandala-Sanchez, said the edited cells "stayed functional under immunosuppression" and "remained sensitive to other drugs". These are laboratory findings. The sources give no patient numbers, no clinical outcomes and no date for the next step, which the team describes as a first-in-human trial.

For now, the people who could gain are those who already live with ongoing immunosuppression: patients with rare immune disorders, transplant recipients and people receiving cell therapies for cancer. If the approach holds up in patients, its appeal is practical. It is built on medicines that routine care already uses, so it asks less of hospitals than a therapy that requires a new drug alongside it. Whether it reaches that stage, and how quickly, depends on a trial the team has not yet run.